Genetic sonography: The historical and clinical role of fetal echocardiography

Ultrasound in Obstetrics and Gynecology

Volumn 35, Issue 5, 2010, Pages 509-521

  Devore, G R ^a  

^a Fetal Diagnostic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

AMNIOCENTESIS; CONGENITAL HEART MALFORMATION; DOWN SYNDROME; ECHOCARDIOGRAPHY; ECHOGRAPHY; EDITORIAL; FEMALE; FETUS ECHOGRAPHY; GENETICS; HISTORY; HUMAN; METHODOLOGY; PREGNANCY; SECOND TRIMESTER PREGNANCY;

ALPHA-FETOPROTEINS; AMNIOCENTESIS; DOWN SYNDROME; ECHOCARDIOGRAPHY; FEMALE; HEART DEFECTS, CONGENITAL; HISTORY, 20TH CENTURY; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; ULTRASONOGRAPHY, PRENATAL;

EID: 77951862148     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.7652     Document Type: Review

References (114)

1. Byard RW. Forensic issues in Down syndrome fatalities. J Forensic Leg Med 2007; 14: 475-481.
2. Hambach R. [Combination of mongolism and congenital heart defects.]. Ann Paediatr 1954; 183: 77-88.
3. Hambach R. [Congenital heart defects combined with mongolism.]. Cas Lek Cesk 1956; 95: 317-321.
4. Esen FM. Congenital heart malformations in mongolism with special reference to ostium atrioventriculare commune. Arch Pediatr 1957; 74: 243-277.
5. DeVore GR. Trisomy 21: 91% detection rate using second-trimester ultrasound markers. Ultrasound Obstet Gynecol 2000; 16: 133-141.
6. DeVore GR. Second trimester ultrasonography may identify 77 to 97% of fetuses with trisomy 18. J Ultrasound Med 2000; 19: 565-576.
7. DeVore GR. The genetic sonogram: its use in the detection of chromosomal abnormalities in fetuses of women of advanced maternal age. Prenat Diagn 2001; 21: 40-45.
8. DeVore GR. Is genetic ultrasound cost-effective? Semin Perinatol 2003; 27: 173-182.
9. DeVore GR. The role of fetal echocardiography in genetic sonography. Semin Perinatol 2003; 27: 160-172.
10. DeVore GR, Alfi O. The use of color Doppler ultrasound to identify fetuses at increased risk for trisomy 21: an alternative for high-risk patients who decline genetic amniocentesis. Obstet Gynecol 1995; 85: 378-386.
11. DeVore GR, Romero R. Combined use of genetic sonography and maternal serum triple-marker screening: an effective method for increasing the detection of trisomy 21 in women younger than 35 years. J Ultrasound Med 2001; 20: 645-654.
12. DeVore GR, Romero R. Genetic sonography: a cost-effective method for evaluating women 35 years and older who decline genetic amniocentesis. J Ultrasound Med 2002; 21: 5-13.
13. DeVore GR, Romero R. Genetic sonography: an option for women of advanced maternal age with negative triple-marker maternal serum screening results. J Ultrasound Med 2003; 22: 1191-1199.
14. Daniel A, Lam-Po-Tang PR. Prenatal diagnosis in New South Wales: comparative view of the first 1000 cases of chromosomal, sex-linked, and metabolic referrals. Med J Aust 1978; 2: 352-357.
15. Golbus MS, Loughman WD, Epstein CJ, Halbasch G, Stephens JD, Hall BD. Prenatal genetic diagnosis in 3000 amniocenteses. N Engl J Med 1979; 300: 157-163.
16. Crandall BF, Lebherz TB, Rubinstein L, Robertson RD, Sample WF, Sarti D, Howard J. Chromosome findings in 2,500 second trimester amniocenteses. Am J Med Genet 1980; 5: 345-356.
17. Kromberg J, Bernstein R, Jenkins T, Bernstein J, Goudie EG, Sneider P. Two years of mid-trimester amniocentesis in Johannesburg. S Afr Med J 1980; 57: 1031-1039.
18. Sepe SJ, Marks JS, Oakley GP, Manley AF. Genetic services in the United States. JAMA 1982; 248: 1733-1735.
19. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984; 1: 926-929.
20. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886-894.
21. Lustig L, Clarke S, Cunningham G, Schonberg R, Tompkin- son G. California's experience with low MS-AFP results. Am J Med Genet 1988; 31: 211-222.
22. Benacerraf BR, Frigoletto FD, Jr., Cramer DW. Down syndrome: sonographic sign for diagnosis in the second-trimester fetus. Radiology 1987; 163: 811-813.
23. Benacerraf BR, Gelman R, Frigoletto FD, Jr. Sonographic identification of second-trimester fetuses with Down's syndrome. N Engl J Med 1987; 317: 1371-1376.
24. Lockwood C, Benacerraf B, Krinsky A, Blakemore K, Belanger K, Mahoney M, Hobbins J. A sonographic screening method for Down syndrome. Am J Obstet Gynecol 1987; 157: 803-808.
25. Benacerraf BR, Cnann A, Gelman R, Laboda LA, Frigo-letto FD, Jr. Can sonographers reliably identify anatomic features associated with Down syndrome in fetuses? Radiology 1989; 173: 377-380.
26. Cuckle H, Wald N, Quinn J, Royston P, Butler L. Ultrasound fetal femur length measurement in the screening for Down's syndrome. Br J Obstet Gynaecol 1989; 96: 1373-1378.
27. Dicke JM, Gray DL, Songster GS, Crane JP. Fetal biometry as a screening tool for the detection of chromosomally abnormal pregnancies. Obstet Gynecol 1989; 74: 726-729.
28. Hill LM, Guzick D, Belfar HL, Hixson J, Rivello D, Rusnak J. The current role of sonography in the detection of Down syndrome. Obstet Gynecol 1989; 74: 620-623.
29. LaFollette L, Filly RA, Anderson R, Golbus MS. Fetal femur length to detect trisomy 21. A reappraisal. J Ultrasound Med 1989; 8: 657-660.
30. Ginsberg N, Cadkin A, Pergament E, Verlinsky Y. Ultrasono-graphic detection ofthe second-trimester fetus with trisomy 18 and trisomy 21. Am J Obstet Gynecol 1990; 163: 1186-1190.
31. Grist TM, Fuller RW, Albiez KL, Bowie JD. Femur length in the US prediction of trisomy 21 and other chromosomal abnormalities. Radiology 1990; 174: 837-839.
32. Marquette GP, Boucher M, Desrochers M, Dallaire L. Screening for trisomy 21 with ultrasonographic determination of biparietal diameter/femur length ratio. Am J Obstet Gynecol 1990; 163: 1604-1605.
33. Nyberg DA, Resta RG, Hickok DE, Hollenbach KA, Luthy DA, Mahony BS. Femur length shortening in the detection of Down syndrome: is prenatal screening feasible? Am J Obstet Gynecol 1990; 162: 1247-1252.
34. Nyberg DA, Resta RG, Luthy DA, Hickok DE, Mahony BS, Hirsch JH. Prenatal sonographic findings of Down syndrome: review of 94 cases. Obstet Gynecol 1990; 76: 370-377.
35. Shah YG, Eckl CJ, Stinson SK, Woods JR, Jr. Biparietal diameter/femur length ratio, cephalic index, and femur length measurements: not reliable screening techniques for Down syndrome. Obstet Gynecol 1990; 75: 186-188.
36. Sheldon TA, Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ 1991; 302: 1133-1136.
37. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha- fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992; 80: 353-358.
38. Piggott M, Wilkinson P, Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. J Med Screen 1994; 1: 45-49.
39. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkki-nen A, Canick JA, Saller DN Jr, Bowers JB. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992; 327: 588-593.
40. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994; 330: 1114-1118.
41. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191: 45-67.
42. Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ, Nicolaides KH. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 1995; 5: 20-25.
43. Benacerraf BR, Neuberg D, Bromley B, Frigoletto FD, Jr. Sonographic scoring index for prenatal detection of chromosomal abnormalities. J Ultrasound Med 1992; 11: 449-458.
44. Lockwood CJ, Lynch L, Ghidini A, Lapinski R, Berkowitz G, Thayer B, Miller WA. The effect of fetal gender on the prediction of Down syndrome by means of maternal serum alpha-fetoprotein and ultrasonographic parameters. Am J Obstet Gynecol 1993; 169: 1190-1197.
45. Nyberg DA, Resta RG, Luthy DA, Hickok DE, Williams MA. Humerus and femur length shortening in the detection of Down's syndrome. Am J Obstet Gynecol 1993; 168: 534-538.
46. Biagiotti R, Periti E, Cariati E. Humerus and femur length in fetuses with Down syndrome. Prenat Diagn 1994; 14: 429-434.
47. Campbell WA, Vintzileos AM, Rodis JF, Ciarleglio L, Craffey A. Efficacy of the biparietal diameter/femur length ratio to detect Down syndrome in patients with an abnormal biochemical screen. Fetal Diagn Ther 1994; 9: 175-182.
48. Donnenfeld AE, Carlson DE, Palomaki GE, Librizzi RJ, Weiner S, Platt LD. Prospective multicenter study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies. Obstet Gynecol 1994; 84: 844-847.
49. Gray DL, Crane JP. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome. Am J Obstet Gynecol 1994; 171: 1282-1286.
50. Bahado-Singh RO, Goldstein I, Uerpairojkit B, Copel JA, Mahoney MJ, Baumgarten A. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results. Am J Obstet Gynecol 1995; 173: 1106-1110.
51. Bromley B, Lieberman E, Laboda L, Benacerraf BR. Echogenic intracardiac focus: a sonographic sign for fetal Down syndrome. Obstet Gynecol 1995; 86: 998-1001.
52. Grandjean H, Sarramon MF. Femur/foot length ratio for detection of Down syndrome: results of a multicenter prospective study. The Association Francaise pour le Depistage et la Prevention des Handicaps de l'Enfant Study Group. Am J Obstet Gynecol 1995; 173: 16-19.
53. Grandjean H, Sarramon MF. Sonographic measurement of nuchal skinfold thickness for detection of Down syndrome in the second-trimester fetus: a multicenter prospective study. The AFDPHE Study Group. Association Francaise pour le Depistage et la Prevention des Handicaps de l'Enfant. Obstet Gynecol 1995; 85: 103-106.
54. Nadel AS, Bromley B, Frigoletto FD, Jr., Benacerraf BR. Can the presumed risk of autosomal trisomy be decreased in fetuses of older women following a normal sonogram? J Ultrasound Med 1995; 14: 297-302.
55. Nyberg DA, Luthy DA, Cheng EY, Sheley RC, Resta RG, Williams MA. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers. Am J Obstet Gynecol 1995; 173: 1030-1035.
56. Rodis JF, Vintzileos AM, Fleming AD, Ciarleglio L, Nardi DA, Feeney L, Scorza WE, Campbell WA, Ingardia C. Comparison of humerus length with femur length in fetuses with Down syndrome. Am J Obstet Gynecol 1991; 165: 1051-1056.
57. Crane JP, Gray DL. Sonographically measured nuchal skinfold thickness as a screening tool for Down syndrome: results of a prospective clinical trial. Obstet Gynecol 1991; 77: 533-536.
58. Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992; 12: 801-806.
59. Wald NJ, Watt HC, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn 1996; 16: 923-926. (Pubitemid 26379896)
60. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1996; 16: 927-929.
61. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011.
62. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
63. Hobbins JC, Lezotte DC, Persutte WH, DeVore GR, Benacerraf BR, Nyberg DA, Vintzileos AM, Platt LD, Carlson DE, Bahado-Singh RO, Abuhamad AZ. An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies. J Ultrasound Med 2003; 22: 33-38.
64. Smith-Bindman R, Chu P, Goldberg JD. Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. Prenat Diagn 2007; 27: 535-544.
65. Szigeti Z, Csaba A, Pete B, Hajdu J, Papp Z, Papp C. Correlation of prenatal sonographic diagnosis and morphologic findings of fetal autopsy in fetuses with trisomy 21. J Ultra-sound Med 2007; 26: 61-8; quiz 69-70.
66. Bottalico JN, Chen X, Tartaglia M, Rosario B, Yarabothu D, Nelson L. Second-trimester genetic sonogram for detection of fetal chromosomal abnormalities in a community-based antenatal testing unit. Ultrasound Obstet Gynecol 2009; 33: 161-168.
67. Vintzileos AM, Campbell WA, Rodis JF, Guzman ER, Smu-lian JC, Knuppel RA. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet Gynecol 1996; 87: 948-952.
68. Cleves MA, Hobbs CA, Cleves PA, Tilford JM, Bird TM, Robbins JM. Congenital defects among liveborn infants with Down syndrome. Birth Defects Res A Clin Mol Teratol 2007; 79: 657-663.
69. Rowe RD, Uchida IA. Cardiac malformation in mongolism: a prospective study of184 mongoloid children. Am J Med 1961; 31: 726-735.
70. Martin GR, Rosenbaum KM, Sardegna KM. Prevalence of heart disease in trisomy 21: An unbiased population. Pediatr Res 1989; 25: 77A.
71. Tubman TR, Shields MD, Craig BG, Mulholland HC, Nevin NC. Congenital heart disease in Down's syndrome: two year prospective early screening study. BMJ 1991; 302: 1425-1427.
72. Khoury MJ, Erickson JD. Improved ascertainment of cardiovascular malformations in infants with Down's syndrome, Atlanta, 1968 through 1989. Implications for the interpretation of increasing rates of cardiovascular malformations in surveillance systems. Am J Epidemiol 1992; 136: 1457-1464.
73. Wells GL, Barker SE, Finley SC, Colvin EV, FinleyWH. Congenital heart disease in infants with Down's syndrome. South Med J1994; 87: 724-727.
74. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ, Saker DM. Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 1998; 80: 213-217.
75. Stoll C, Alembik Y, Dott B, Roth MP. Study of Down syndrome in 238,942 consecutive births. Ann Genet 1998; 41: 44-51.
76. McElhinney DB, Straka M, Goldmuntz E, Zackai EH. Correlation between abnormal cardiac physical examination and echocardiographic findings in neonates with Down syndrome. Am J Med Genet 2002; 113: 238-241.
77. Nisli K, Oner N, Candan S, Kayserili H, Tansel T, Tireli E, Karaman B, Omeroglu RE, Dindar A, Aydogan U, Başaran S, Ertugrul T. Congenital heart disease in children with Down's syndrome: Turkish experience of 13 years. Acta Cardiol 2008; 63: 585-589.
78. Paladini D, Tartaglione A, Agangi A, Teodoro A, Forleo F, Borghese A, Martinelli P. The association between congenital heart disease and Down syndrome in prenatal life. Ultrasound Obstet Gynecol 2000; 15: 104-108.
79. Axt-Fliedner R, Schwarze A, Smrcek J, Germer U, Krapp M, Gembruch U. Isolated ventricular septal defects detected by color Doppler imaging: evolution during fetal and first year of postnatal life. Ultrasound Obstet Gynecol 2006; 27: 266-273.
80. Nir A, Driscoll DJ, Edwards WD. Intrauterine closure of membranous ventricular septal defects: mechanism of closure in two autopsy specimens. Pediatr Cardiol 1994; 15: 33-37.
81. Paladini D, Palmieri S, Lamberti A, Teodoro A, Martinelli P, Nappi C. Characterization and natural history of ventricular septal defects in the fetus. Ultrasound Obstet Gynecol 2000; 16: 118-122.
82. Azancot A, Diehl R, Dorgeret S, Sebag G, Baumann C, Vuil- lard E, Machado L, Luton D, Oury JF. Isolated pericardial effusion in the human fetus: a report of three cases. Prenat Diagn 2003; 23: 193-197.
83. Sharland G, Lockhart S. Isolated pericardial effusion: an indication for fetal karyotyping? Ultrasound Obstet Gynecol 1995; 6: 29-32.
84. Kusanagi Y, Ochi H, Matsubara K, Ito M. Hypereosinophilic syndrome in a trisomy 21 fetus. Obstet Gynecol 1998; 92: 701-702.
85. Huggon IC, Ghi T, Cook AC, Zosmer N, Allan LD, Nicolaides KH. Fetal cardiac abnormalities identified prior to 14 weeks' gestation. Ultrasound Obstet Gynecol 2002; 20: 22-29.
86. Huggon IC, Defigueiredo DB, Allan LD. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11-14 weeks of gestation. Heart 2003; 89: 1071-1073.
87. Faiola S, Tsoi E, Huggon IC, Allan LD, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan. Ultrasound Obstet Gynecol 2005; 26: 22-27.
88. Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 2006; 27: 151-155.
89. Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method. Ultrasound Obstet Gynecol 2006; 27: 609-612.
90. Borrell A. Promises and pitfalls of first trimester sonographic markers in the detection of fetal aneuploidy. Prenat Diagn 2009; 29: 62-68.
91. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH. Tricuspid regurgitation in screeningfor trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 18-22.
92. Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005; 29: 190-194.
93. Devore GR, Alfi O. The association between an abnormal nuchal skin fold, trisomy 21, and ultrasound abnormalities identified during the second trimester of pregnancy. Ultrasound Obstet Gynecol 1993; 3: 387-394.
94. Brown DL, Roberts DJ, Miller WA. Left ventricular echogenic focus in the fetal heart: pathologic correlation. J Ultrasound Med 1994; 13: 613-616.
95. Wax JR, Royer D, Mather J, Chen C, Aponte-Garcla A, Steinfeld JD, Ingardia CJ. A preliminary study of sonographic grading of fetal intracardiac echogenic foci: feasibility, reliability and association with aneuploidy. Ultrasound Obstet Gynecol 2000; 16: 123-127.
96. Winter TC, Anderson AM, Cheng EY, Komarniski CA, Souter VL, Uhrich SB, Nyberg DA. Echogenic intracardiac focus in 2nd-trimester fetuses with trisomy 21: usefulness as a US marker. Radiology 2000; 216: 450-456.
97. Huggon IC, Cook AC, Simpson JM, Smeeton NC, Shar-land GK. Isolated echogenic foci in the fetal heart as marker of chromosomal abnormality. Ultrasound Obstet Gynecol 2001; 17: 11-16.
98. Anderson N, Jyoti R. Relationship of isolated fetal intracardiac echogenic focus to trisomy 21 at the mid-trimester sonogram in women younger than 35 years. Ultrasound Obstet Gynecol 2003; 21: 354-358.
99. Sotiriadis A, Makrydimas G, Ioannidis JP. Diagnostic performance of intracardiac echogenic foci for Down syndrome: a meta-analysis. Obstet Gynecol 2003; 101: 1009-1016.
100. Carrico A, Matias A, Areias JC. How important is a cardiac echogenic focus in a routine fetal examination? Rev Port Cardiol 2004; 23: 459-461.
101. Coco C, Jeanty P, Jeanty C. An isolated echogenic heart focus is not an indication for amniocentesis in 12,672 unselected patients. J Ultrasound Med 2004; 23: 489-496.
102. Koklanaris N, Roman AS, Perle MA, Monteagudo A. Isolated echogenic intracardiac foci in patients with low-risk triple screen results: assessing the risk of trisomy 21. J Perinat Med 2005; 33: 539-542.
103. Shanks AL, Odibo AO, Gray DL. Echogenic intracardiac foci: associated with increased risk for fetal trisomy 21 or not? J Ultrasound Med 2009; 28: 1639-1643.
104. DeVore G. The isolated echogenic intracardiac focus in fetuses with trisomy 21: the role of echocardiography. 0P01.16. Ultrasound Obstet Gynecol 2006; 28: 416.
105. Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialard F, Giudicelli Y, Ville Y. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006; 195: 1379-1387.
106. Aagaard-Tillery KM, Malone FD, Nyberg DA, Porter TF, Cuckle HS, Fuchs K, Sullivan L, Comstock CH, Saade GR, Eddleman K, Gross S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk Research Consortium. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009; 114: 1189-1196.
107. Yeo L, Vintzileos AM. The use of genetic sonography to reduce the need for amniocentesis in women at high-risk for Down syndrome. Semin Perinatol 2003; 27: 152-159.
108. Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A. BJOG 2001; 108: 1043-1046.
109. Vintzileos AM, Guzman ER, Smulian JC, Day-Salvatore DL, Knuppel RA. Indication-specific accuracy of second-trimester genetic ultrasonography for the detection of trisomy 21. Am J Obstet Gynecol 1999; 181: 1045-1048.
110. Vintzileos AM, Guzman ER, Smulian JC, Yeo L, Scorza WE, Knuppel RA. Down syndrome risk estimation after normal genetic sonography. Am J Obstet Gynecol 2002; 187: 1226-1229.
111. Verdin SM, Economides DL. The role of ultrasonographic markers for trisomy 21 in women with positive serum biochemistry. Br J Obstet Gynaecol 1998; 105: 63-67.
112. Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams MA. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998; 12: 8-14.
113. Watson WJ, Miller RC, Menard MK, Chescheir NC, Katz VL, Hansen WF, Wolf EJ. Ultrasonographic measurement of fetal nuchal skin to screen for chromosomal abnormalities. Am J Obstet Gynecol 1994; 170: 583-586.
114. Vergani P, Locatelli A, Piccoli MG, Ceruti P, Mariani E, Pezzullo JC, Ghidini A. Best second trimester sonographic markers for the detection of trisomy 21. J Ultrasound Med 1999; 18: 469-473.